Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.

SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia / E. Tiacci, A. Mancini, M. Marchetti, G.M. D'Elia, A. Candoni, A. Morotti, A. Romano, A. Gozzetti, A. Broccoli, L. De Carolis, R. Bruna, M.C. Tisi, C. Selleri, M. Capponi, D. Vallisa, C. Cattaneo, M.G. Della Porta, A. Busca, B. Falini, M. Massaia, L. Bertù, A. Pulsoni, P. Rivela, P. Corradini, F. Passamonti. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 1365-2141. - 201:3(2023), pp. 411-416. [10.1111/bjh.18606]

SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia

A. Mancini
Secondo
;
P. Corradini;F. Passamonti
2023

Abstract

Little is known of the course of COVID-19 and the antibody response to infection or vaccination in patients with hairy-cell leukaemia (HCL). Among a total of 58 HCL cases we studied in these regards, 37 unvaccinated patients, mostly enjoying a relatively long period free from anti-leukaemic treatment, developed COVID-19 between March 2020 and December 2021 with a usually favourable outcome (fatality rate: 5/37, 14%); however, active leukaemia, older age and more comorbidities were associated with a worse course. Postinfection (n = 11 cases) and postvaccination (n = 28) seroconversion consistently developed, except after recent anti-CD20 or venetoclax therapy, correlating with perivaccine B-cell count. Vaccination appeared to protect from severe COVID-19 in 11 patients with breakthrough infection.
COVID-19; anti-SARS-CoV-2 vaccination; hairy-cell leukaemia; post-COVID-19 seroconversion
Settore MED/15 - Malattie del Sangue
2023
20-dic-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
Br J Haematol - 2022 - Tiacci - SARS‐CoV‐2 infection and vaccination in patients with hairy‐cell leukaemia.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 481.66 kB
Formato Adobe PDF
481.66 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/969279
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact